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Background
Genomic analyses have shown that melanoma patients
have hundreds to thousands of non-synonymous muta-
tions including unique tumor associated antigens (TAA)
that can be recognized by their immune systems. The
efficacy of anti-checkpoint monoclonal antibodies pro-
vides further proof that host recognition of TAA exists,
but many patients do not benefit from such therapy,
perhaps because they lack sufficient TAA recognition.
One way to enhance TAA recognition is immunization.
The best source of TAA may be autologous tumor cells
that self-renew and proliferate in tissue culture (patient
specific tumor stem cells). Sequential Phase II trials in
metastatic melanoma patients tested the clinical benefit
of repeated s.c. injections of autologous dendritic cells
loaded with antigens from irradiated tumor cells derived
from autologous melanoma cell lines (DC-TC), and sus-
pended in GM-CSF. In a single arm trial 5-year survival
was 50% for 54 patients treated with DC-TC. In a ran-
domized Phase II trial, 2-year survival was 72% for 18
DC-TC patients compared to 31% in the control arm
(HR = 0.27, p = 0.007). Toxicities associated with DC-
TC were minimal (n = 72). Improvements in manufac-
turing have increased the probability of establishing a
cell line and decreased the time needed to produce the
product. Melapuldencel-T (DC-TC) has shown sufficient
promise to receive special product assessment (SPA)
and fast track designation in association with approval
of this pivotal Phase III trial.
Trial design
This is a Phase III, double-blinded, randomized, placebo-
controlled trial. Eligible patients will have stage IV or
recurrent stage III melanoma with at least one lesion
amenable to surgical resection. Resected tumor is trans-
ferred to a manufacturing facility where a cell suspension
is placed in specially formulated cell culture media, then
cells from spheroids are isolated, and then expanded to at
least 100 million cells. After successful establishment of a
cell line and referral for treatment, 250 patients with good
performance status (ECOG 0-1) will be stratified by
whether they have no evidence of disease, non-measurable
disease by RECIST, or measureable disease with elevated
LDH or without elevated LDH. They undergo leukapher-
esis, and are randomized 2:1 to receive either DC-TC or
autologous mononuclear cells. Both products are sus-
pended in 500 µg of GM-CSF and injected weekly for
3 weeks, and then monthly for 5 months. The endpoint is
overall survival with death from any cause the major end-
point. [NCT01875653].
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